multiple sessions of group or individual counseling, where one RCT randomized participants to web-based counseling, proactive telephone-based counseling, or both modalities [57]. Therapy randomization from baseline to EOT was to five different pharmacotherapies [NRT, BUP, PLA, VAR or combined NRT and BUP (NRT+BUP)], which could be combined with different behavioral therapies [group counseling (five or seven sessions), individual counseling (six, seven or eight sessions), and web-based counseling, proactive telephone-based counseling, or both]. Combined PG sizes at EOT were 748, 595, 479, 487, and 324, respectively. Most RCT arms received no further therapy from EOT to 6MO; individuals in the two arms that received NRT+BUP from baseline to EOT were randomized to several pharmacologic and behavioral treatments from EOT to 6MO (See Table, Supplemental Digital Content 4), resulting in a total of seven different PGs at 6MO, the five original PGs, chronic NRT and BUP (CNRT+BUP), and chronic BUP and NRT (CBUP+NRT). Combined PG sizes at 6MO were the same for the first four PGs and 161, 98, and 65, respectively, for the three NRT+BUP PGs. Seven RCTs performed biochemical verification of abstinence [56,58,59,60,61,62]. All RCTs evaluated seven day point prevalence abstinence at EOT (eight to 12 weeks post-quit), and at
